David A. Spellman - 28 Feb 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: SVP, CFO and Treasurer
Signature: /s/ Carolyn Rucci, attorney-in-fact for David A. Spellman
Issuer symbol: AKBA
Transactions as of: 28 Feb 2022
Net transactions value: -$17,689
Form type: 4
Filing time: 02 Mar 2022, 20:09:23 UTC
Previous filing: 01 Oct 2021
Next filing: 10 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Sale	$15,946	-7,400	-9.6%	$2.15	69,402	28 Feb 2022	Direct	F1
transaction	AKBA	Common Stock	Award	$0	+60,000	+86%	$0.000000	129,402	28 Feb 2022	Direct	F2
transaction	AKBA	Common Stock	Sale	$1,743	-803	-0.62%	$2.17	128,599	01 Mar 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Employee Stock Option (Right to buy)	Award	$0	+225,000		$0.000000	225,000	28 Feb 2022	Common Stock	225,000	$2.16	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2	The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F3	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
F4	The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.